InvestorsHub Logo
Followers 4
Posts 1139
Boards Moderated 0
Alias Born 04/27/2006

Re: maumar post# 5299

Friday, 10/06/2017 5:28:01 PM

Friday, October 06, 2017 5:28:01 PM

Post# of 8545
"A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma



This study is not yet open for participant recruitment.
See Contacts and Locations

Verified September 2017 by Janssen Research & Development, LLC

Sponsor:

Janssen Research & Development, LLC


ClinicalTrials.gov Identifier:

NCT03301220

First Posted: October 4, 2017

Last Update Posted: October 4, 2017"

Another Phase III trial starting.


Never argue with a fool, for after awhile, it becomes difficult to determine which is the fool.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News